Heartbeam
Logotype for Heartbeam Inc

Heartbeam (BEAT) investor relations material

Heartbeam Q3 2026 earnings summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Heartbeam Inc
Q3 2026 earnings summary12 Nov, 2026

Executive summary

  • Heart attack assessment became the primary strategic focus, with FDA Breakthrough Device Designation, TAP acceptance and agreement on a 510(k) pathway advancing the program.

  • ALIGN-ACS showed comparable HeartBeam 3D ECG accuracy to standard 12-lead ECG; a U.S. pivotal study is planned to begin in Q1 2027.

  • Q3 losses, expenses and cash use declined; approximately $4.0M of Q4 ATM proceeds lifted unaudited pro forma cash to $10.1M.

  • The FDA-cleared system is limited to arrhythmia assessment; heart attack detection and AI applications remain investigational.

Financial highlights

  • Q3 operating expenses were $3.457M, down from $5.092M in Q2 2026 and $5.290M in Q3 2025; net loss was $3.010M versus $5.039M and $5.255M, respectively.

  • Q3 net loss per share was $0.05 versus $0.10 in Q2 2026 and $0.15 in Q3 2025; nine-month net loss was $12.749M versus $15.713M.

  • Nine-month operating expenses were $13.265M versus $15.829M; R&D was $6.816M versus $10.096M, while SG&A was $6.449M versus $5.733M.

  • No revenue was generated through September 30, 2026; no material commercial revenue is expected in 2026.

Outlook and guidance

  • FY2026 net operating cash outflow guidance is $12.0M–$12.5M, reduced from prior guidance of less than $14M; baseline Q4 operating cash outflow is expected below $2.5M.

  • Pivotal-study design is targeted for completion in Q4 2026, with enrollment planned for Q1 2027 and completion targeted by mid-2027; accelerated timing could increase Q4 spending.

  • Management described a likely pivotal study of about 300 patients across 8–10 centers; FDA agreement on study size and endpoints remains pending.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
Research faster. Power your platform.

Next Heartbeam earnings date

Logotype for Heartbeam Inc
Virtual Best Ideas Winter Investment Conference8 Dec, 2026
Heartbeam
Cover every name on your watchlist this earnings season.
Automations, AI chat, and live calls across 16,000+ companies.
Book demo

Next Heartbeam earnings date

Logotype for Heartbeam Inc
Virtual Best Ideas Winter Investment Conference8 Dec, 2026

AI chat

Ask anything. Verify everything.

Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn more

Automations

Zero in on what matters

Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more

Live audio & transcripts

Be first

Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more

Quartr MCP connects your AI environment to 17K+ public companies

Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more

Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.

Jamie Ross

Investment Manager, GAM Investments

GAM
GAM

Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.

Tom O'Hara

Investment Director

Ciena
Ciena

Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.

Gregg Lampf

VP of Investor Relations

Frequently asked questions

HeartBeam, Inc. is a medical technology company focused on developing innovative cardiac care solutions. The company’s primary product is a proprietary 3D-vector ECG platform designed to assist in the detection and diagnosis of heart attacks and other cardiac conditions. HeartBeam aims to provide more accurate and accessible cardiac care tools, enabling healthcare professionals to monitor and diagnose heart-related issues in both clinical and remote settings. The company serves the healthcare industry, particularly in the fields of cardiology and emergency medicine, with a focus on improving diagnostic accuracy and patient outcomes. The company is headquartered in Santa Clara, California, and its shares are listed on the NASDAQ.